Atria Wealth Solutions Inc. Has $2.84 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Atria Wealth Solutions Inc. lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 5,110 shares of the company’s stock after selling 39 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in IDEXX Laboratories were worth $2,836,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in IDXX. Gotham Asset Management LLC boosted its position in shares of IDEXX Laboratories by 79.9% in the third quarter. Gotham Asset Management LLC now owns 17,427 shares of the company’s stock valued at $7,620,000 after acquiring an additional 7,741 shares during the period. NewEdge Wealth LLC boosted its holdings in IDEXX Laboratories by 30.4% in the 3rd quarter. NewEdge Wealth LLC now owns 639 shares of the company’s stock valued at $279,000 after purchasing an additional 149 shares during the period. Assenagon Asset Management S.A. grew its position in IDEXX Laboratories by 25.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 43,593 shares of the company’s stock worth $24,196,000 after purchasing an additional 8,831 shares during the last quarter. Carderock Capital Management Inc. increased its holdings in shares of IDEXX Laboratories by 35.7% during the 4th quarter. Carderock Capital Management Inc. now owns 16,416 shares of the company’s stock worth $9,112,000 after purchasing an additional 4,315 shares during the period. Finally, Mitchell Capital Management Co. raised its position in shares of IDEXX Laboratories by 1.3% during the third quarter. Mitchell Capital Management Co. now owns 6,372 shares of the company’s stock valued at $2,786,000 after buying an additional 79 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $499.30 on Monday. The company has a quick ratio of 1.17, a current ratio of 1.57 and a debt-to-equity ratio of 0.42. The firm has a market cap of $41.47 billion, a PE ratio of 49.58, a price-to-earnings-growth ratio of 3.85 and a beta of 1.26. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39. The company’s 50-day moving average price is $531.02 and its two-hundred day moving average price is $511.63.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.12 by $0.20. The company had revenue of $901.60 million during the quarter, compared to analysts’ expectations of $891.88 million. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. IDEXX Laboratories’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 earnings per share. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on IDXX. Piper Sandler lowered IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target on the stock. in a research note on Tuesday, January 30th. Barclays upped their target price on IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. The Goldman Sachs Group lifted their price target on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. JPMorgan Chase & Co. raised their price objective on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Finally, William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $591.50.

Insider Transactions at IDEXX Laboratories

In related news, SVP George Fennell sold 8,198 shares of IDEXX Laboratories stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the transaction, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, SVP George Fennell sold 8,198 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the sale, the senior vice president now owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Brian P. Mckeon sold 23,326 shares of the company’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total value of $13,296,053.26. Following the transaction, the chief financial officer now directly owns 29,718 shares in the company, valued at approximately $16,939,557.18. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 43,524 shares of company stock worth $24,871,960. Insiders own 2.18% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.